Format

Send to

Choose Destination
See comment in PubMed Commons below
Curr Opin Organ Transplant. 2012 Dec;17(6):675-80. doi: 10.1097/MOT.0b013e32835a66a1.

Allogeneic stem cell transplantation for ischemic myocardial dysfunction.

Author information

1
Athersys Inc., Cleveland, Ohio 44115, USA. ating@athersys.com

Abstract

PURPOSE OF REVIEW:

Stem cell therapy for the treatment of cardiovascular disease is rapidly moving from bench to bedside. In the settings of acute and chronic myocardial injury, approaches to treatment have explored various cell populations, delivery methods, and times of administration.

RECENT FINDINGS:

Although initial studies in patients were performed with unfractionated bone marrow cells, further investigations in animal models of myocardial disease have elucidated mechanisms of benefit and opened doors to treatment strategies with stem cells of varied derivation.

SUMMARY:

Allogeneic stem cell populations have demonstrated therapeutic promise in ischemic heart disease, without a requirement for immunosuppressive drugs, and offer the potential to create large-scale, cryopreserved banks of cells for 'off the shelf' utility.

PMID:
23111647
DOI:
10.1097/MOT.0b013e32835a66a1
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Lippincott Williams & Wilkins
    Loading ...
    Support Center